04:50 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
22:55 , Nov 15, 2018 |  BC Innovations  |  Product R&D

Tempest takes PPAR alpha into cancer

Tempest Therapeutics Inc.’s first data from its preclinical PPARα program gave it the support it was looking for to repurpose the cardiovascular target for cancer. Tapping into the emerging field of cancer immuno-metabolism, Tempest is...
18:17 , Jun 13, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Liver cancer, colorectal cancer Cell culture and mouse studies suggest inhibiting CPT1A alone or in combination with VEGF inhibition could help treat hepatocellular carcinoma and colorectal cancer. In a mouse colorectal cancer cell line...
15:18 , Apr 13, 2018 |  BC Week In Review  |  Clinical News

China FDA approves IND for Canbridge's GBM candidate

Canbridge Life Sciences Ltd. (Beijing, China) said China FDA approved an IND to begin a Phase II/III trial of asunercept (APG101, CAN-008) to treat glioblastoma multiforme (GBM). A spokesperson told BioCentury that Canbridge plans to...
03:45 , Apr 13, 2018 |  BC Innovations  |  Targets & Mechanisms

Meeting the burden

A major theme at this year’s AACR is the abundance of preclinical discovery driven by molecular signatures in patient samples, suggesting the research community is heeding the call for studies better grounded in human data,...
23:02 , Feb 8, 2018 |  BC Innovations  |  Translation in Brief

Proteomic pathfinding

Biognosys is using a method developed by ETHZ researchers for the unbiased detection of molecular targets based on protein-metabolite interactions to study inter- and intra-patient variances in the proteome. The protein services CRO will also...
01:13 , Dec 13, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Melanoma Mouse studies suggest FASL inhibitors could help treat immunotherapy-resistant melanoma. In a mouse model of immunotherapy-resistant melanoma, a fusion protein consisting of Fas receptor and the Fc region of murine IgG2A (Fas-Fc) that...
21:50 , Dec 1, 2017 |  BC Week In Review  |  Company News

Boehringer launches open-access preclinical platform

Boehringer Ingelheim GmbH (Ingelheim, Germany) launched a platform to provide researchers worldwide with open, free access to select molecules in the preclinical stage. The platform, opn.ME , comprises 19 compounds that Boehringer has deemed suitable...
22:03 , Nov 20, 2017 |  BC Extra  |  Company News

Boehringer launches open-access preclinical platform

Boehringer Ingelheim GmbH (Ingelheim, Germany) launched a platform to provide researchers worldwide with open and free access to select preclinical-stage molecules. The platform, opn.ME , comprises 19 compounds that Boehringer has deemed suitable for preclinical...
22:43 , Nov 16, 2017 |  BC Extra  |  Preclinical News

FAS/FASL pathway involved in immunotherapy resistance

A study published in Nature Communications by researchers at the Ludwig Institute for Cancer Research and colleagues identified Fas ligand (TNF superfamily, member 6; FASL) as a potential target to overcome resistance to cancer immunotherapy...